At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 733 enrolled
Drug / intervention
Proxalutamide (GT0918) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness
In Brief
A Phase 3 clinical trial evaluating Proxalutamide (GT0918) and Placebo for Efficacy and Safety. Completed, enrolled 733 participants across 8 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEfficacy and Safety
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartMar 2021
First PostedMay 2021
Primary CompletionJan 2022
Study CompletionApr 2022
TodayJul 2026
First PostedMay 3, 2021
Enrollment StartMar 5, 2021
Primary CompletionJan 24, 2022
Study CompletionApr 6, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.2 years ago
Interventions
Proxalutamide (GT0918)drug
Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
Placebodrug
Placebo+Standard of care determined by PI and local regulatory